GlassScriptPhysician profile
Kelly E Earnest
NPI 1366437238
$3,875.29
in general payments reported to CMS, 2019-2025
30 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 97% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $315 · 2022: $600 · 2023: $824 · 2024: $962 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,871 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,870.85 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $591.51 | 2022-2025 | Dupixent |
| Genzyme Corporation | $500.69 | 2022-2025 | |
| Janssen Biotech, INC. | $475.88 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $404.63 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $404.42 | 2021-2023 | |
| Qol Medical, LLC | $307.06 | 2022-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $306.67 | 2021-2025 | Eohilia, Gattex |
| Alcresta Therapeutics, INC. | $221.50 | 2023-2024 | Relizorb |
| Madrigal Pharmaceuticals | $86.32 | 2025 | Rezdiffra |
| Mirum Pharmaceuticals, INC. | $80.33 | 2022-2024 | Livmarli |
| Gilead Sciences, INC. | $52.01 | 2025 | |
| Celltrion USA INC. | $37.93 | 2025 | Vegzelma |
| Janssen Scientific Affairs, LLC | $35.63 | 2021 | |
| Kaleo, INC. | $35.00 | 2022 | |
| Organon LLC | $31.43 | 2023-2024 | Hadlima |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.29 | 2022-2023 | Avsola, Amjevita |
| Aimmune Therapeutics, INC. | $27.68 | 2025 | Zenpep |
| Fresenius Kabi USA, LLC | $27.16 | 2023 | Idacio |
| Ars Pharmaceuticals Operations, INC. | $26.28 | 2025 | Neffy |
| Ipsen Biopharmaceuticals, INC | $26.23 | 2025 | Bylvay |
| Novo Nordisk INC | $21.28 | 2025 | Wegovy |
| Medtronic, INC. | $21.23 | 2024 | Interstim |
| Rhythm Pharmaceuticals, INC. | $18.32 | 2025 | Imcivree |
| Genentech USA, INC. | $18.14 | 2024 | Xolair |
| Orphalan INC | $17.41 | 2025 | Cuvrior |
| Albireo Pharma, INC. | $15.16 | 2022 | |
| Endogastric Solutions, INC | $14.38 | 2023 | Esophyx |
| Sandoz INC. | $14.07 | 2023 | Hyrimoz |
| Pfizer INC. | $13.66 | 2021 | |
| Vivus LLC | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Earnest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.